Clinical Data REGENXBIO slumps after serious side effects mar Duchenne gene therapy results BioSpaceShares of REGENXBIO declined 37% on a mixed data readout and other updates from the company's first quarter earnings call Thursday.Gene Therapy PlatformRead full story pharminent May 14, 2026 (Last updated: May 21, 2026) BioSpace Shares of REGENXBIO declined 37% on a mixed data readout and other updates from the company’s first quarter earnings call Thursday. Gene Therapy Platform Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Biogen takes tau Alzheimer’s therapy to Phase 3 despite mid-stage fail, prompting cautious optimismNext: Trial miss doesn’t dent Biogen’s faith in Alzheimer’s drug Related Stories Clinical Data Boehringer advances duo for aggressive cancers into phase 3 pharminent June 22, 2026 Clinical Data Edgewise slides as cardiomyopathy challenger to BMS, Cytokinetics falls short pharminent June 17, 2026 Clinical Data EHA26: BMS touts positive multiple myeloma data for two pipeline candidates pharminent June 17, 2026
